Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... BACKGROUND: Pure red cell aplasia and moderate aplastic anemia are marrow failure ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

    ... risks associated with transfusions, chronic anemia and red blood cell (RBC) transfusion dependence impact negatively on survival and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

    ... the response is variable and some patients remain red blood cell transfusion -dependent. In 72 patients with hemolytic Paroxysmal ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... expected with the aging population. Treatment includes red blood cell transfusion for anemia . The immunomodulatory agents ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... Five of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... Low endogenous erythropoietin levels and limited red blood cell transfusion history can predict response to ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 07/20/2018 - 5:15pm.